Next generation treatment of pancreatic cancer

Xerient is focused on unmet needs in cancer treatment, particularly in abdominal and gastrointestinal cancers.
Xerient is pursuing the development of novel therapeutic technology that can dramatically improve the survival of these patients.

NOW ENROLLING

XER-001 Phase 1/2a Clinical Trial

Xerient has initiated a Phase 1/2a clinical trial evaluating XER-001 in combination with stereotactic body radiotherapy (SBRT) in patients with locally advanced pancreatic cancer.

The study is currently recruiting patients at leading U.S. cancer centers and oncology practices, including:

City of Hope Duarte and Irvine, California

Karmanos Cancer Institute Detroit, Michigan

CHRISTUS St. Vincent Regional Cancer Center Santa Fe, New Mexico

Oncology Consultants, P.A. Houston, Texas

Partners

We are introducing a portfolio of products that will address hard to treat cancers in the abdominal/GI area, beginning with solutions for pancreatic cancer.

Radioprotective Therapeutic

XER-001 is designed to selectively protect the duodenum during radiotherapy, with the goal of enabling the delivery of effective radiation treatment for patients with locally advanced pancreatic cancer.

A Phase 1/2a clinical trial of XER-001 is now enrolling patients in the United States.

Xerient aims to change how pancreatic cancer is treated

Targeting unmet needs in the Pancreatic cancer space
Advancing proven technologies, that can be redeployed as novel approaches for cancer care
Repurposing of an already FDA-approved drug (not development of a new one), oral administration of the drug already proven clinically safe
An experienced team advancing XER-001 through clinical, regulatory and strategic development.
Complimentary and supplementary to other standards of care treatments
Applicable to other Abdominal & Gastrointestinal Tract cancers

Pancreatic Cancer

The pancreas is an organ with functions that are critical to proper digestion and the absorption of nutrients in the body. Its location, adjacent to the intestines, which are highly sensitive to radiation, hinders the use of radiotherapy in treating pancreatic cancer. As no early stage diagnostic is available, the disease is usually discovered at a very late stage.

40
Years

Survival has not improved substantially over nearly 40 years

55,440
Patients

55,440 diagnosed with pancreatic cancer in the U.S. alone and 495,000 worldwide

1st
Mortality rate

Highest mortality rate of all major cancers

3rd
Cancer related deaths

3rd leading cause of cancer-related death in the US surpassing breast cancer

74%
Mortality within 1 year

74% of patients die within the 1st year of diagnosis, and 91% of pancreatic cancer patients will die within 5 years of diagnosis

2nd
Deaths by 2030

2nd leading cause of cancer-related death in the US by the year 2030, surpassing colorectal cancer

We will advance care for pancreatic cancer to detect it earlier, and with more reliability. We will expand the possibilities for cancer care through a solution that promotes radiotherapy as a real alternative for treatment.